Aberrant FGFR4 activity drives activation of signaling pathways that promote cell proliferation, survival, and invasion, as observed in epithelial cancers such as non-small cell lung cancer, breast cancer, and prostate cancer [45,46]. This evidence concerns the gene FGFR4 and prostate carcinoma.